The OMEGA-7 clinical trial has achieved a significant milestone, reaching its target enrollment of 2,400 participants three months ahead of the projected timeline. This accelerated enrollment reflects the growing interest in neural enhancement technologies and the trust participants place in Unzyme Laboratories’ research programs.
Global Participation
Participants have been enrolled from 23 countries across six continents, making OMEGA-7 one of the most geographically diverse clinical trials in the field of neural augmentation. This diversity is crucial for understanding how our technologies perform across different genetic backgrounds and populations.
“The overwhelming response to OMEGA-7 demonstrates that people around the world are ready to embrace the next phase of human evolution,” noted Dr. Eleanor Strömberg, Director of Clinical Operations. “We’re particularly encouraged by the quality of our participant pool—their commitment to advancing science is truly remarkable.”
What Happens Next
With enrollment complete, all participants will now proceed through the standardized baseline assessment protocol. This comprehensive evaluation establishes individual neurological benchmarks against which enhancement outcomes will be measured.
The trial will proceed in three phases:
- Baseline Phase (Months 1-2): Complete neurological mapping and cognitive assessment
- Integration Phase (Months 3-8): Staged implementation of neural enhancement protocols
- Evaluation Phase (Months 9-18): Long-term monitoring and outcome assessment
Participant Support
All enrolled participants have access to our dedicated trial support team, available around the clock to address questions and concerns. Local clinical coordinators at each of our 47 trial sites provide hands-on support throughout the study.
Compensation packages, as outlined in participant agreements, will be distributed according to the established schedule. Participants requiring travel assistance should contact their site coordinator.
Important Reminders
- All participants must maintain their scheduled assessment appointments
- Report any unusual symptoms immediately through the trial hotline
- Do not discontinue any prescribed medications without consulting trial physicians
- The consent withdrawal period has now closed for Phase I participants
We thank all participants for their contribution to this historic research effort. Together, we are advancing the frontier of human potential.
For general inquiries about our clinical trial programs, please visit our trials page.